Idiopathic pulmonary fibrosis: Early detection and referral

Justin Oldham, Imre Noth

Research output: Contribution to journalReview article

20 Citations (Scopus)

Abstract

Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.

Original languageEnglish (US)
Pages (from-to)819-829
Number of pages11
JournalRespiratory Medicine
Volume108
Issue number6
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Idiopathic Pulmonary Fibrosis
Interstitial Lung Diseases
Referral and Consultation
Idiopathic Interstitial Pneumonias
Lung Transplantation
Quality of Life
Clinical Trials
Lung
Survival

Keywords

  • ILD
  • IPF
  • Lung transplant
  • Pulmonary fibrosis

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Idiopathic pulmonary fibrosis : Early detection and referral. / Oldham, Justin; Noth, Imre.

In: Respiratory Medicine, Vol. 108, No. 6, 01.01.2014, p. 819-829.

Research output: Contribution to journalReview article

@article{17a9a22a733c4aad986ca5a57c21854a,
title = "Idiopathic pulmonary fibrosis: Early detection and referral",
abstract = "Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.",
keywords = "ILD, IPF, Lung transplant, Pulmonary fibrosis",
author = "Justin Oldham and Imre Noth",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.rmed.2014.03.008",
language = "English (US)",
volume = "108",
pages = "819--829",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",
number = "6",

}

TY - JOUR

T1 - Idiopathic pulmonary fibrosis

T2 - Early detection and referral

AU - Oldham, Justin

AU - Noth, Imre

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.

AB - Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause or cure, is the most common and deadly of the idiopathic interstitial pneumonias. With a median survival of 3-5 years following diagnosis, IPF is characterized by a progressive decline in lung function and quality of life in most patients. Vigilance among clinicians in recognizing IPF early in the disease course remains critical to properly caring for these patients, as this provides the widest range of management options. When IPF is suspected, a multidisciplinary evaluation (MDE) by a clinician, radiologist and pathologist with ILD expertise should occur, as this improves diagnostic agreement in both community and academic settings. When community MDE is not possible, or diagnostic doubt exists, referral to an ILD center should be considered. ILD center referral may also provide access specialized care, including clinical trials and lung transplantation, and should be considered for any patient with an established diagnosis of IPF.

KW - ILD

KW - IPF

KW - Lung transplant

KW - Pulmonary fibrosis

UR - http://www.scopus.com/inward/record.url?scp=84902244179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902244179&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2014.03.008

DO - 10.1016/j.rmed.2014.03.008

M3 - Review article

C2 - 24746629

AN - SCOPUS:84902244179

VL - 108

SP - 819

EP - 829

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

IS - 6

ER -